Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDB018 in advanced solid tumors
NCT04840394Phase 1Completed
- Sponsor
- Eikon Therapeutics
- Start
- Jun 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BDB018 in solid tumor (2 arms), sponsored by Eikon Therapeutics. Primary endpoints: Adverse Events at 30 months and Dose Limiting Toxicity at 21 days. Started Jun 2021; status: completed.
02
Drugs
BDB018
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04840394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840394.